1010 related articles for article (PubMed ID: 29016894)
41. ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma.
Arrillaga-Romany I; Gardner SL; Odia Y; Aguilera D; Allen JE; Batchelor T; Butowski N; Chen C; Cloughesy T; Cluster A; de Groot J; Dixit KS; Graber JJ; Haggiagi AM; Harrison RA; Kheradpour A; Kilburn LB; Kurz SC; Lu G; MacDonald TJ; Mehta M; Melemed AS; Nghiemphu PL; Ramage SC; Shonka N; Sumrall A; Tarapore RS; Taylor L; Umemura Y; Wen PY
J Clin Oncol; 2024 May; 42(13):1542-1552. PubMed ID: 38335473
[TBL] [Abstract][Full Text] [Related]
42. Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults.
Schulte JD; Buerki RA; Lapointe S; Molinaro AM; Zhang Y; Villanueva-Meyer JE; Perry A; Phillips JJ; Tihan T; Bollen AW; Pekmezci M; Butowski N; Oberheim Bush NA; Taylor JW; Chang SM; Theodosopoulos P; Aghi MK; Hervey-Jumper SL; Berger MS; Solomon DA; Clarke JL
Neurooncol Adv; 2020; 2(1):vdaa142. PubMed ID: 33354667
[TBL] [Abstract][Full Text] [Related]
43. Infiltrative gliomas of the thalamus in children: the role of surgery in the era of H3 K27M mutant midline gliomas.
Dorfer C; Czech T; Gojo J; Hosmann A; Peyrl A; Azizi AA; Kasprian G; Dieckmann K; Filbin MG; Haberler C; Roessler K; Slavc I
Acta Neurochir (Wien); 2021 Jul; 163(7):2025-2035. PubMed ID: 33090244
[TBL] [Abstract][Full Text] [Related]
44. Deep Learning for Noninvasive Assessment of H3 K27M Mutation Status in Diffuse Midline Gliomas Using MR Imaging.
Li J; Zhang P; Qu L; Sun T; Duan Y; Wu M; Weng J; Li Z; Gong X; Liu X; Wang Y; Jia W; Su X; Yue Q; Li J; Zhang Z; Barkhof F; Huang RY; Chang K; Sair H; Ye C; Zhang L; Zhuo Z; Liu Y
J Magn Reson Imaging; 2023 Sep; 58(3):850-861. PubMed ID: 36692205
[TBL] [Abstract][Full Text] [Related]
45. H3F3A K27M mutation in pediatric CNS tumors: a marker for diffuse high-grade astrocytomas.
Gielen GH; Gessi M; Hammes J; Kramm CM; Waha A; Pietsch T
Am J Clin Pathol; 2013 Mar; 139(3):345-9. PubMed ID: 23429371
[TBL] [Abstract][Full Text] [Related]
46. Adult diffuse midline gliomas H3 K27-altered: review of a redefined entity.
López-Pérez CA; Franco-Mojica X; Villanueva-Gaona R; Díaz-Alba A; Rodríguez-Florido MA; Navarro VG
J Neurooncol; 2022 Jul; 158(3):369-378. PubMed ID: 35567713
[TBL] [Abstract][Full Text] [Related]
47. A rare case of adult diffuse midline glioma with H3 K27M mutant in the prepontine cistern.
Chen X; Zhong L; Lin J; Yu J
J Int Med Res; 2021 Jan; 49(1):300060520981266. PubMed ID: 33435779
[TBL] [Abstract][Full Text] [Related]
48. Pediatric Diffuse Midline Gliomas H3 K27M-Mutant and Non-Histone Mutant Midline High-Grade Gliomas in Neurofibromatosis Type 1 in Comparison With Non-Syndromic Children: A Single-Center Pilot Study.
Garibotto F; Madia F; Milanaccio C; Verrico A; Piccardo A; Tortora D; Piatelli G; Diana MC; Capra V; Garrè ML; Rossi A; Morana G
Front Oncol; 2020; 10():795. PubMed ID: 32582540
[No Abstract] [Full Text] [Related]
49. Detecting the H3F3A mutant allele found in high-grade pediatric glioma by real-time PCR.
Zhang R; Han J; Daniels D; Huang H; Zhang Z
J Neurooncol; 2016 Jan; 126(1):27-36. PubMed ID: 26376656
[TBL] [Abstract][Full Text] [Related]
50. Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience.
Neth BJ; Balakrishnan SN; Carabenciov ID; Uhm JH; Daniels DJ; Kizilbash SH; Ruff MW
J Neurooncol; 2022 Mar; 157(1):91-100. PubMed ID: 35076860
[TBL] [Abstract][Full Text] [Related]
51. H3 G34-mutant high-grade glioma.
Lim KY; Won JK; Park CK; Kim SK; Choi SH; Kim T; Yun H; Park SH
Brain Tumor Pathol; 2021 Jan; 38(1):4-13. PubMed ID: 32995948
[TBL] [Abstract][Full Text] [Related]
52. Significance of H3K27M Mutation in "Nonmidline" High-Grade Gliomas of Cerebral Hemispheres.
La Rocca G; Sabatino G; Altieri R; Signorelli F; Ricciardi L; Gessi M; Della Pepa GM
World Neurosurg; 2019 Nov; 131():174-176. PubMed ID: 31415896
[TBL] [Abstract][Full Text] [Related]
53. Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes.
Huang T; Garcia R; Qi J; Lulla R; Horbinski C; Behdad A; Wadhwani N; Shilatifard A; James C; Saratsis AM
Oncotarget; 2018 Dec; 9(98):37112-37124. PubMed ID: 30647848
[TBL] [Abstract][Full Text] [Related]
54. A case of diffuse midline glioma, H3 K27M mutant mimicking a hemispheric malignant glioma in an elderly patient.
Fujioka Y; Hata N; Hatae R; Suzuki SO; Sangatsuda Y; Nakahara Y; Mizoguchi M; Iihara K
Neuropathology; 2020 Feb; 40(1):99-103. PubMed ID: 31762138
[TBL] [Abstract][Full Text] [Related]
55. Diffuse midline gliomas with histone H3-K27M mutation: A rare case with PNET-like appearance and neuropil-like islands.
Gao Y; Feng YY; Yu JH; Li QC; Qiu XS; Wang EH
Neuropathology; 2018 Apr; 38(2):165-170. PubMed ID: 28880421
[TBL] [Abstract][Full Text] [Related]
56. An H3F3A K27M-mutation in a sonic hedgehog medulloblastoma.
Dottermusch M; Uksul N; Knappe UJ; Erdlenbruch B; Wefers AK
Brain Pathol; 2022 May; 32(3):e13024. PubMed ID: 34747078
[TBL] [Abstract][Full Text] [Related]
57. Molecular and clinical characterization of H3 K27M-mutant "non-midline" glioblastoma: A case report and literature review.
Onishi S; Ohba S; Kuraoka K; Kurashige T; Sugiyama K; Yamasaki F
Neurocirugia (Astur : Engl Ed); 2022; 33(6):356-360. PubMed ID: 36333093
[TBL] [Abstract][Full Text] [Related]
58. Diffuse midline glioma H3 K27M-mutant in adults: A report of six cases and literature review.
Alzoubi H; Maraqa B; Hasasna N; Giangaspero F; Antonelli M; Gianno F; Arcella A; Al-Hussaini M
Clin Neuropathol; 2021; 40(2):108-117. PubMed ID: 33191898
[TBL] [Abstract][Full Text] [Related]
59. A long-term survivor of pediatric midline glioma with H3F3A K27M and BRAF V600E double mutations.
Nakano Y; Yamasaki K; Sakamoto H; Matsusaka Y; Kunihiro N; Fukushima H; Inoue T; Honda-Kitahara M; Hara J; Yoshida A; Ichimura K
Brain Tumor Pathol; 2019 Oct; 36(4):162-168. PubMed ID: 31254135
[TBL] [Abstract][Full Text] [Related]
60. H3 K27M-altered glioma and diffuse intrinsic pontine glioma: Semi-systematic review of treatment landscape and future directions.
van den Bent M; Saratsis AM; Geurts M; Franceschi E
Neuro Oncol; 2024 May; 26(Supplement_2):S110-S124. PubMed ID: 38102230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]